ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

Cooperative Group chairmen Cool, But High Priority Trials To Continue

January 18, 1991

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

April 16, 2004

Nexavar Phase III Trial Fails To Meet Primary Endpoint

June 29, 2012

ODACSupports Temodal For Treatment of Astrocytoma

January 22, 1999

NCI Community Cancer Centers RFP Issued; Advisors Criticize Project Structure.

November 10, 2006

Managed Care: Cancer Panel Finds Need “Critical” For Cost, Outcomes Data

September 13, 1996